{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:37:10Z","timestamp":1793831830107,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277086"],"award-info":[{"award-number":["22277086"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2022ZDZX0028"],"award-info":[{"award-number":["2022ZDZX0028"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2023YFH0099"],"award-info":[{"award-number":["2023YFH0099"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejmech.2025.117893","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T19:25:27Z","timestamp":1750447527000},"page":"117893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Discovery of degrader for FLT3, GSPT1 and IKZF1\/3 proteins merging PROTAC and molecular glue targeting FLT3-ITD mutant acute myeloid leukemia"],"prefix":"10.1016","volume":"296","author":[{"given":"Yu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7913-0283","authenticated-orcid":false,"given":"Yongmei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117893_bib1","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"Short","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117893_bib2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s11864-023-01090-3","article-title":"Update on small molecule targeted therapies for acute myeloid leukemia","volume":"24","author":"Wang","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117893_bib3","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021011694","article-title":"How I treat pediatric acute myeloid leukemia","volume":"138","author":"Rubnitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117893_bib4","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2025.117893_bib5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.ejmech.2025.117893_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810328","article-title":"Recent advances in PROTACs for drug targeted protein research","volume":"23","author":"Yao","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117893_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41589-019-0414-3","article-title":"Molecular glue concept solidifies","volume":"16","author":"Baek","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117893_bib8","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117893_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cbpa.2019.11.012","article-title":"Targeted protein pegradation: current and future challenges","volume":"56","author":"Hanzl","year":"2020","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117893_bib10","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.drudis.2020.03.012","article-title":"Fundamental aspects of DMPK optimization of targeted protein degraders","volume":"25","author":"Cantrill","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.117893_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107477","article-title":"Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of acute myeloid leukemia","volume":"149","author":"Ye","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117893_bib12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117893_bib13","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","article-title":"Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients","volume":"111","author":"Bacher","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117893_bib14","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-Like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2025.117893_bib15","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/cncr.28705","article-title":"Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations","volume":"120","author":"Alvarado","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2025.117893_bib16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117893_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/biomedicines8080245","article-title":"Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"8","author":"Eguchi","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2025.117893_bib18","doi-asserted-by":"crossref","first-page":"16497","DOI":"10.1021\/acs.jmedchem.1c00996","article-title":"Proteolysis-targeting chimera(PROTAC) modification of dovitinib enhances the antiproliferative effect against FLT3-ITD-positive acute myeloid leukemia cells","volume":"64","author":"Cao","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117893_bib19","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.jmedchem.0c01489","article-title":"CC-90009: a cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia","volume":"64","author":"Hansen","year":"2021","journal-title":"J. Med. Chem."},{"issue":"7611","key":"10.1016\/j.ejmech.2025.117893_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117893_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cancergencyto.2009.08.010","article-title":"Differential expression of GSPT1 GGCn alleles in cancer","volume":"195","author":"Vacas","year":"2009","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.ejmech.2025.117893_bib22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acschembio.7b00969","article-title":"Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders","volume":"13","author":"Ishoey","year":"2018","journal-title":"ACS Chem. Biol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117893_bib23","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1021\/acs.jmedchem.0c01313","article-title":"Identification of potent, selective, and orally bioavailable small molecule GSPT1\/2 degraders from a focused library of cereblon modulators","volume":"64","author":"Nishiguchi","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117893_bib24","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/ijms22031103","article-title":"Role of aiolos and ikaros in the antitumor and immunomodulatory activity of IMiDs in multiple myeloma: better to lose than to find them","volume":"22","author":"Cippitelli","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117893_bib25","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1182\/blood.2019002655","article-title":"IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia","volume":"136","author":"Song","year":"2020","journal-title":"Blood"},{"issue":"6168","key":"10.1016\/j.ejmech.2025.117893_bib26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117893_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1015372322419","article-title":"Aiolos and ikaros: regulators of lymphocyte development, homeostasis and lymphoproliferation","volume":"7","author":"Schmitt","year":"2002","journal-title":"Apoptosis"},{"key":"10.1016\/j.ejmech.2025.117893_bib28","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117893_bib29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117893_bib30","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1021\/acs.jmedchem.9b00846","article-title":"Simple structural modifications converting a bona fide MDM2 PROTAC degrader into a molecular glue molecule: a cautionary tale in the design of PROTAC degraders","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117893_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113425","article-title":"Development of MDM2 degraders based on ligands derived from ugireactions: lessons and discoveries","volume":"219","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117893_bib32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-141461","article-title":"Nx-2127, a degrader of BTK and IMiD neosubstrates, for the treatment of B-Cell malignancies","volume":"136","author":"Robbins","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117893_bib33","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2021-147473","article-title":"Nx-5948, a selective degrader of BTK with activity in preclinical models of hematologic and brain malignancies","volume":"138","author":"Robbins","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ejmech.2025.117893_bib34","doi-asserted-by":"crossref","first-page":"10548","DOI":"10.1021\/acs.jmedchem.3c01823","article-title":"Discovery of KT-413, a targeted protein degrader of IRAK4 and IMiD substrates targeting MYD88 mutant diffuse large B-Cell lymphoma","volume":"67","author":"Weiss","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117893_bib35","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1038\/s41388-022-02340-8","article-title":"Gang. Greg. Wang, discovery of a dual WDR5 and ikaros PROTAC degrader as an anti-cancer therapeutic","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.ejmech.2025.117893_bib36","doi-asserted-by":"crossref","first-page":"12403","DOI":"10.1021\/acs.jmedchem.0c00696","article-title":"Small-molecule Fms-like tyrosine kinase 3 inhibitors: an attractive and efficient method for the treatment of acute myeloid leukemia","volume":"63","author":"Zhong","year":"2020","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2025.117893_bib37","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1200\/JCO.2022.40.16_suppl.7025","article-title":"BTX-1188, a first-in-class dual degrader of GSPT1 and IKZF1\/3, for treatment of acute myeloid leukemia (AML) and solid tumors","volume":"40","author":"Chourasia","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117893_bib38","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","article-title":"Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer","volume":"62","author":"Han","year":"2019","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117893_bib39","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/acsmedchemlett.1c00178","article-title":"PROTAC-Mediated degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer","volume":"12","author":"Kargbo","year":"2021","journal-title":"ACS Med. Chem. Lett."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425006580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425006580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T08:45:51Z","timestamp":1754988351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425006580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":39,"alternative-id":["S0223523425006580"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117893","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of degrader for FLT3, GSPT1 and IKZF1\/3 proteins merging PROTAC and molecular glue targeting FLT3-ITD mutant acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117893"}}